The Use of Digital Mobile Technology for Rapid Assessment of Treatment Induced Cognitive Deficits in Multiple Myeloma Patients.

Patients with multiple myeloma may experience subjective changes in baseline cognitive function, which can span across various cognitive domains. Currently, there is limited data about the nature, severity, and temporal evolution of these deficits, as well as their relationship with disease and treatment-related factors. While advances in multiple myeloma treatments continue, few prospective trials have evaluated their impact on cognitive function and quality of life. The objective of this retrospective, cross sectional study is to assess potential cognitive changes in multiple myeloma patients undergoing therapy. This study aims to recruit approximately 60 participants, with 16 presently enrolled. To identify incidence and patterns of cognitive change, patients undergo comprehensive cognitive evaluations such as the International Cognition and Cancer Task Force (ICCTF) battery, National Institute of Health Toolbox (NIB-TB), and the five-minute Montreal Cognitive Assessment screener (MoCA). Data collection and preliminary analysis on 16 participants (median age 72 years, 10/16 on first-line therapy) has revealed global cognitive impairment in 5/16 patients using the ICCTF battery and the NIH-TB, with verbal learning and memory, and executive function being the most affected domains. Future initiatives of this research will focus on expanding study population with the aim to validate preliminary trends in a larger cohort. Larger numbers will allow exploration of correlations between subjective and objective cognitive performance, and the potential differential impact of classes of treatment agents on cognitive function. Results from this study may yield hypotheses for future evaluation and validation in larger, prospective trials.